期刊
FOODS
卷 11, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/foods11213415
关键词
endometrial cancer; Ishikawa; isorhamnetin; UPR response; mitochondria
资金
- National Natural Science Foundation of Ningxia Province [2021AAC02019]
- Youth talent cultivation project of North Minzu University [2021KYQD27, FWNX14]
- Major Projects of Science and Technology in Anhui Province [201903a06020021]
- Key research and development projects in Ningxia province [2021BEF02013]
- King Saud University (Riyadh, Saudi Arabia) [RSP-2021/138]
Isorhamnetin has shown potential as a promising medicinal material for the treatment of endometrial cancer, as it can induce apoptosis and inhibit metastasis through multiple pathways.
Endometrial cancer (EC) is a very common female cancer which has attracted more and more attention. According to the individual patient's condition, the current treatment of EC patients is mainly based on surgery, which is supplemented by chemotherapy, radiotherapy, and endocrine intervention. However, these existing treatment strategies also have some inevitable limitations. Therefore, it is particularly important to find an active ingredient with low toxicity and a high safety profile against EC. Isorhamnetin is a flavonoid known to be present in a variety of plants, such as sea buckthorn, dry willow, and wolfberry. In recent years, the anti-tumor effects of isorhamnetin have been reported. In our study, isorhamnetin was shown to induce apoptosis in Ishikawa cells by inducing the endogenous mitochondrial apoptotic pathway and exogenous death receptor pathway, promoting the endoplasmic reticulum stress-related pathway, and activating the corresponding markers of UPR response. In addition, isorhamnetin affected the expression of MMP2 and MMP9-related proteins in vitro and in vivo and eventually repressed metastasis. Therefore, isorhamnetin can be used as a promising medicinal material for the treatment of EC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据